Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China

Li, Jinzhong; Gong, Xiaohua; Wang, Zhigang; Chen, Renzhou; Li, Taoyuan; Zeng, Daobing; Li, Min‐ran

doi:10.1016/j.virusres.2020.198043

Cited by 129 publications

(118 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

114

Contrasting

Order By: Relevance

“…T cells are the key mediators of antiviral immune responses, and studies of lymphocytes in patients with COVID-19 are beginning to emerge (8). Lymphopenia is the hallmark of severe COVID-19 presentation (9), and studies from small series of patients suggest this affects T cells, B cells, and NK cells (10)(11)(12)(13). Recipients of cellular therapies, including allogeneic hematopoietic cell transplantation (Allo), autologous hematopoietic cell transplantation (Auto), and CD19-directed chimeric antigen receptor T cell (CAR T) therapy, constitute a unique population of patients with hematologic malignancies, due to their immune dysregulation and prolonged timeline for immune reconstitution.…”

Section: Introductionmentioning

confidence: 99%

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Shah¹,

DeWolf²,

Lee³

et al. 2020

Journal of Clinical Investigation

111

209

View full text Add to dashboard Cite

BACKGROUND. Understanding outcomes and immunologic characteristics of cellular therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving therapies in the COVID-19 era. In this study of recipients of allogeneic (Allo) and autologous (Auto) hematopoietic cell transplant and CD19-directed chimeric antigen receptor T cell (CAR T) therapy at Memorial Sloan Kettering Cancer Center, we aimed to identify clinical variables associated with COVID-19 severity and assess lymphocyte populations. METHODS. We retrospectively investigated patients diagnosed between March 15, 2020, and May 7, 2020. In a subset of patients, lymphocyte immunophenotyping, quantitative real-time PCR from nasopharyngeal swabs, and SARS-CoV-2 antibody status were available. RESULTS. We identified 77 patients with SARS-CoV-2 who were recipients of cellular therapy (Allo, 35; Auto, 37; CAR T, 5; median time from cellular therapy, 782 days; IQR, 354-1611 days). Overall survival at 30 days was 78%. Clinical variables significantly associated with the composite endpoint of nonrebreather or higher oxygen requirement and death (n events = 25 of 77) included number of comorbidities (HR 5.41, P = 0.004), infiltrates (HR 3.08, P = 0.032), and neutropenia (HR 1.15, P = 0.04). Worsening graft-versus-host disease was not identified among Allo recipients. Immune profiling revealed reductions and rapid recovery in lymphocyte populations across lymphocyte subsets. Antibody responses were seen in a subset of patients. CONCLUSION. In this series of Allo, Auto, and CAR T recipients, we report overall favorable clinical outcomes for patients with COVID-19 without active malignancy and provide preliminary insights into the lymphocyte populations that are key for the antiviral response and immune reconstitution.

show abstract

Section: Introductionmentioning

confidence: 99%

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Shah¹,

DeWolf²,

Lee³

et al. 2020

Journal of Clinical Investigation

111

209

View full text Add to dashboard Cite

show abstract

“…Currently, the zoonotic coronavirus disease 2019 (COVID- 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is dramatically challenging global health systems. COVID-19 exhibits a diverse spectrum of clinical manifestations, ranging from a moderate course of infection with no or mild symptoms to viral pneumonia and hospitalization particularly in patients at risk, ultimately requiring intensive care unit (ICU) admission in case of acute respiratory distress syndrome (ARDS) (1,2). Factors determining clinical outcome include patient age, chronic pulmonary and heart disease, as well as excessive production of the inflammatory mediators interleukin 6 (IL-6) and 8 (IL-8) (3,4).…”

Section: Introductionmentioning

confidence: 99%

SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition

Sattler¹,

Angermair²,

Stockmann³

et al. 2020

Journal of Clinical Investigation

194

201

View full text Add to dashboard Cite

“…Later, it became known that a new type of enveloped RNA betacoronavirus, officially named severe acute respiratory syndrome coronavirus 2] (SARS-CoV-2), had emerged. 1 In January 30, 2020, the (World Health Organization (WHO) declared a public health emergency of international concern, 2 and in March 11, 2020, recognized as a global pandemic. 3…”

Section: Introductionmentioning

confidence: 99%

Extrapulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations

Pousa¹,

Mendonça²,

Oliveira³

et al. 2021

Jornal de Pediatria

View full text Add to dashboard Cite

Objective The aim of this review was to summarize the most common extrapulmonary manifestations in pediatric patients with COVID-19, as well as to discuss clinical, epidemiological, and pathophysiological aspects of these clinical presentations in children. Source of data An extensive search of literature was performed in order to identify pediatric cases with extrapulmonary manifestations between January 1, 2020 and June 21, 2020. Generic keywords, such as “Novel coronavirus” or “Novel coronavirus 2019” or “2019 nCoV” or “COVID-19” or “SARS-CoV-2” were searched on PubMed database, associated either with age filters or generic pediatric terms. Summary of findings A total of 28 articles, including 199 patients, were considered suitable to review and data extraction. The main findings were summarized in tables. The main non-pulmonary manifestations in pediatric patients, in decreasing order of frequency, were gastrointestinal, renal, cardiovascular, neurological, hematological and lymphatic, cutaneous, hepatic, ocular, olfactory, and gustatory. Multisystem impairment and Kawasaki-like disease were also described. Conclusions Differences in immune response of children and variations of tissue expression of angiotensin converting enzyme 2, the virus receptor, are likely to influence clinical, epidemiological, and pathophysiological patterns of the disease.

show abstract

Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China

Cited by 129 publications

References 12 publications

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition

Extrapulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations

Contact Info

Product

Resources

About